The coronavirus supplemental appropriations bill (H.R. 6379) introduced in the House on 23 March would increase both US pharmaceutical manufacturing capacity and scrutiny of foreign pharmaceutical supply chain risks, reflecting growing concerns among US legislators about foreign dependence, particularly on China.
This would all be done as a response to the COVID-19 viral outbreak that, because it began in China and...